Scarica l'app Stockscreener
1.22
3.94%
-0.05
Dopo l'orario di chiusura:
1.20
-0.02
-1.64%
Precedente Chiudi:
$1.27
Aprire:
$1.25
Volume 24 ore:
159.65K
Relative Volume:
0.99
Capitalizzazione di mercato:
$35.18M
Reddito:
$40.58M
Utile/perdita netta:
$-80.65M
Rapporto P/E:
-0.3663
EPS:
-3.331
Flusso di cassa netto:
$-8.11M
1 W Prestazione:
+0.83%
1M Prestazione:
-3.56%
6M Prestazione:
-47.41%
1 anno Prestazione:
-20.78%
Intervallo 1D:
$1.18
$1.33
Intervallo di 1 settimana:
$1.16
$1.43
Portata 52W:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Nome
Celularity Inc
Settore
Industria
Telefono
(908) 768-2170
Indirizzo
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.22 | 35.18M | 40.58M | -80.65M | -8.11M | -3.331 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-30 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-06 | Downgrade | Truist | Buy → Hold |
| 2022-01-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Celularity Inc Borsa (CELU) Ultime notizie
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com India
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
Biomaterial deal aims to triple NEXGEL sales and turn profit - Stock Titan
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
NexGel to Acquire Celularity Biomaterials Assets and Exclusive License in Deal Up to $35 Million - TradingView
Deal to triple NEXGEL (NASDAQ: NXGL) revenue and add profits - Stock Titan
Celularity Sells and Licenses Biomaterials Portfolio to NexGel in Deal Worth Up to $35 Million - TradingView
Celularity (Nasdaq: CELU) monetizes biomaterials in $35M license, pivots to longevity - Stock Titan
Biotechnology company Celularity Inc. recently announced a significant personnel change. - Bitget
NEXGEL, Inc. to Acquire Regenerative Biomaterial Portfolio from Celularity, Anticipating Tripled Revenue and Immediate Profitability - Quiver Quantitative
Biotechnology company Celularity Inc. (NASDAQ: CELU) has recently reached a strategic licensing agreement totaling 35 million dollars. - Bitget
NEXGEL Signs Definitive Agreement to License and Acquire - GlobeNewswire
Celularity Inc. Announces Strategic Partnership to Commercialize Biomaterials Portfolio, Generating Up to $35 Million in Payments - Quiver Quantitative
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
Celularity’s $35M license shifts focus to placental longevity therapies - Stock Titan
NexGel secures regenerative biomaterials portfolio from Celularity in landmark transaction - MSN
Celularity names John Sprague acting CFO following executive departure - Investing.com Nigeria
CELU SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Celularity Inc a defensive stockPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
Will Celularity Inc. stock reach all time highs in 2026Weekly Loss Report & Reliable Price Action Trade Plans - Naître et grandir
Take Profit: Is Celularity Inc Equity Warrant impacted by rising ratesJuly 2025 Price Swings & Stock Market Timing Techniques - baoquankhu1.vn
Aug Shorts: What is Celularity Inc Equity Warrants revenue forecastJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Celularity names John Sprague acting CFO following executive departure By Investing.com - Investing.com India
Joseph Dossantos, Acting CFO, Leaves Celularity On Feb 27, 2026SEC Filing - TradingView
Celularity Inc Announces Departure of Joseph Dossantos as Svp, Finance, Effective February 27, 2026 - marketscreener.com
CELU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CELUW SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CELUW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Portfolio Update: Is Celularity Inc Equity Warrant forming higher highs and higher lows2025 Volatility Report & Safe Capital Allocation Plans - baoquankhu1.vn
Celularity receives $12.2 million from sale of tax credits - Investing.com Nigeria
CELU PE Ratio & Valuation, Is CELU Overvalued - Intellectia AI
Aug Outlook: What are the risks of holding Celularity IncWeekly Risk Report & Fast Gain Swing Alerts - baoquankhu1.vn
CELUWCelularity Inc Latest Stock News & Market Updates - Stock Titan
Guidance Update: How do insiders feel about Celularity IncWeekly Trade Summary & Real-Time Volume Spike Alerts - baoquankhu1.vn
Treasury Yields: Can Celularity Inc maintain sales growthMarket Activity Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Earnings Beat: Should I buy Epsium Enterprise Limited stock nowWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Trend Review: Can Celularity Inc Equity Warrant keep up with sector leaders2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Risk Off: Is MiMedx Group Inc stock a smart retirement pickCPI Data & Precise Buy Zone Tips - baoquankhu1.vn
Celularity Inc Azioni (CELU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):